Search Results
Sep 10, 2026, 06:23 ET Trust Industry Turns to Peer Collaboration and Education as Technology, AI and Fiduciary Pressures Reach a Critical Inflection Point
executives, fiduciary professionals, and industry subject matter experts to explore issues affecting trust organizations today and in the future.ATO's 2026 next Annual Meeting is in Park City, Utah, September 21-23, chaired by Bill McFadden, President and CEO of GreenHill Investment Reporting."Assembling
More news about: GreenHill Investment Reporting
Aug 07, 2026, 08:45 ET Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need,
More news about: Atossa Therapeutics Inc
Jul 28, 2026, 08:30 ET Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
abemaciclibSEATTLE, July 28, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet
More news about: Atossa Therapeutics Inc
Jul 23, 2026, 08:01 ET Knox Systems Partners with Microsoft to Accelerate Secure Government Access to Commercial Innovation on Microsoft Azure
managed cloud environments, supporting more than 70 software companies and maintaining 16 US Federal and Department of War Authorizations to Operate (ATOs). Customers including Adobe, Armis, Celonis, BigID, and other leading software providers rely on Knox to bring commercial innovation to government faster
More news about: Knox Systems, Inc
Jul 23, 2026, 06:30 ET LAZARD REPORTS SECOND QUARTER AND FIRST HALF 2026 RESULTS
Healthcare's Fund IV and Uplift's Fund I. In addition, Lazard advised Thoreau on fundraising and its investment in Ensemble Health and on financing for Atos, DomusVi, and Loxam.Lazard's restructuring and liability management practice has been engaged in a broad range of mandates including debtor roles
More news about: Lazard
Jul 21, 2026, 08:30 ET Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
syndromeSEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet
More news about: Atossa Therapeutics Inc
Jun 24, 2026, 11:44 ET Africa Data Center Market Investment to Reach USD 8.76 Billion by 2031, as South Africa, Kenya, Nigeria, and Egypt Emerge as Strategic Hubs - Arizton
Major Players in the Africa Data CenterIT Infrastructure ProvidersArista NetworksAtosBroadcomCiscoDell TechnologiesFujitsuHewlett Packard Enterprise (HPE)Hitachi VantaraHuawei
More news about: Arizton Advisory & Intelligence
Jun 22, 2026, 03:46 ET AI in Energy Market Projected to Reach USD 22.2 Billion by 2033, AI Adoption Across Utilities and Renewable Energy Systems Fuels Strong Market Growth
analytics and machine learning technologies.Major participants identified by Grand View Research include Siemens AG, ABB, General Electric, C3.ai, Atos SE, Flex Ltd., AppOrchid Inc., Uptake Technologies, Origami Energy Ltd., Alpiq, and SmartCloud Inc.These companies are investing heavily in product
More news about: Grand View Research, Inc
Jun 12, 2026, 17:30 ET Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Jun 11, 2026, 08:00 ET Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
warrantsSEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Jun 10, 2026, 08:35 ET Former DHL Express Latin America CEO Joakim Thrane Joins CEO Coaching International as Partner and Coach
cultures, earning the distinction of #1 Great Place to Work in Latin America.Prior to DHL, Thrane held several senior leadership roles at Atos, including CEO responsibility for the South America business. Across both organizations, he led large-scale operational, commercial, and customer experience
More news about: CEO Coaching International
May 27, 2026, 08:30 ET Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
SEATTLE, May 27, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet
More news about: Atossa Therapeutics Inc
May 20, 2026, 16:45 ET Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
researchSEATTLE, May 20, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical
More news about: Atossa Therapeutics Inc
May 14, 2026, 08:30 ET Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
TrialsSEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet
More news about: Atossa Therapeutics Inc
May 08, 2026, 08:45 ET Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need,
More news about: Atossa Therapeutics Inc
May 08, 2026, 08:32 ET ITAÚ UNIBANCO - Fato Relevante: Mudança de portal de notícias
artigo 3º, § 4º, II, da Resolução CVM 44/21, que realizou a substituição do portal de notícias com página na internet utilizado para divulgação de seus atos e fatos relevantes. A Companhia passará a realizar referidas divulgações no portal
More news about: Itaú Unibanco Holding S.A.
May 06, 2026, 15:56 ET Cellebrite Government Cloud erhält die FedRAMP-Zulassung der Stufe „High"
Strafverfolgung und Nachrichtendienste konzipiert sind. Das Autorisierungsmodell „Einmal einrichten, vielfach nutzen" ermöglicht es Behörden, ihre eigenen ATOs zu beschleunigen, indem sie vorhandene Sicherheitspakete nutzen.Cellebrite Government Cloud ist auf dem
More news about: Cellebrite
May 06, 2026, 08:30 ET Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
SEATTLE, May 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Atossa or the Company) (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focused on developing novel therapies targeting breast cancer and rare diseases, today announced the publication
More news about: Atossa Therapeutics Inc
May 06, 2026, 08:30 ET Cellebrite Government Cloud Achieves FedRAMP High Authorization
protect highly sensitive law enforcement and intelligence data. The "do once, use many" authorization model allows agencies to accelerate their own ATOs by leveraging existing security packages.Cellebrite Government Cloud is available on the
More news about: Cellebrite
May 06, 2026, 08:30 ET Cellebrite Government Cloud Achieves FedRAMP High Authorization
protect highly sensitive law enforcement and intelligence data. The "do once, use many" authorization model allows agencies to accelerate their own ATOs by leveraging existing security packages.Cellebrite Government Cloud is available on the
More news about: Cellebrite
May 05, 2026, 00:01 ET Think 2026: IBM Makes Digital Sovereignty Operational with General Availability of IBM Sovereign Core
with pre-vetted IBM, third-party and open source software and services from an ecosystem of software and infrastructure partners that includes: AMD, ATOS, Cegeka, Cloudera, Dell, Elastic, HCL, Intel, Mistral, MongoDB, and Palo Alto Networks.CPU, GPU, and AI inference environments can be provisioned
More news about: IBM
May 05, 2026, 00:01 ET Think 2026: IBM Delivers the Blueprint for the AI Operating Model as the AI Divide Widens
applications, or populated with pre-vetted IBM, third-party and open-source software and services from an ecosystem of partners that includes: AMD, ATOS, Cegeka, Cloudera, Dell, Elastic, HCL, Intel, Mistral, MongoDB and Palo Alto Networks.Built on open, enterprise-grade technologies like Red
More news about: IBM
May 04, 2026, 08:30 ET Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
approvalSEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical
More news about: Atossa Therapeutics Inc
Apr 28, 2026, 08:00 ET OTAVA Appoints Donnie Gerault as CEO
managed cloud services industry. He has successfully led multiple tech companies as CEO and most recently served as a senior executive at both Lenovo and Atos."We are thrilled to welcome Donnie to the OTAVA team," said John Reardon, President and CEO of OTAVA's parent company Schurz Communications. "His
More news about: OTAVA
Apr 22, 2026, 10:15 ET Digital Twins in Healthcare Market worth $101.19 billion by 2031 | MarketsandMarkets™
Services, Inc. (US), Dassault Systèmes (France), GE Healthcare (US), IBM (US), NVIDIA Corporation (US), Oracle Corporation (US), PTC (US), SAP (Germany), Atos SE (France), ANSYS, Inc. (US), Faststream Technologies (US), Rescale, Inc. (US), Twin Health (US), NUREA (France), Predictiv (US), Verto (Canada), Qbio
More news about: MarketsandMarkets